NF-kB targeting therapy
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
54
NCT05905328
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 28, 2023
Completion: Jun 30, 2027
Loading map...